References
Kaye SB, Khayat D, Aapro MS, Diehl V (1992) Who should receive a 5-HT3 antagonist? Lancet 340:1107–1108
Aapro MS (1992) Pharmacological treatment of delayed emesis. In: Bianchi AM (ed) Mechanisms and control of emesis. Libbey Eurotext, London, pp 141–146
Eguchi K, Ohmatsu H, Karato A, et al (1993) A randomized cross-over study of granisetron+dexamethasone vs high-dose metoclopramide+dx in patients with high-dose cddp contained chemotherapy. Proc Am Soc Clin Oncol Annu Meet 12:431
Carmichael J, Bessell E, Hutcheon A (1993) Iv granisetron vs iv granisetron plus iv dexamethasone in the prophylaxis of emesis induced by cytotoxic chemotherapy. Eur J Cancer 29:S206
Kirchner V, Aapro M, Terrey JP, Alberto P (1993) A placebo controlled double-blind randomised crossover study comparing granisetron with granisetron plus dexamethasone. Eur J Cancer 29:S208
Sorbe B (1993) Tropisetron in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. Ann Oncol 4 [Suppl 35]:39–43
Aapro MS (1993) “... Setron”: are 5-HT3 receptor antagonists different? Eur J Cancer 29:1655
Kirchner V (1993) Clinical studies to assess the economic impact of new therapies: pragmatic approaches to measuring costs. Anticancer Drugs 4 [Suppl 4]:13–20
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aapro, M.S. Once more: prevention of nausea and emesis in cancer treatment. Support Care Cancer 2, 141–142 (1994). https://doi.org/10.1007/BF00417470
Issue Date:
DOI: https://doi.org/10.1007/BF00417470